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a  b  s  t  r  a  c  t
Erectile  dysfunction  (ED)  affected  the  lives  of more  than  300  million  men  worldwide.  Erectile  dysfunc-
tion  drugs  (EDD),  known  as  phosphodiesterase  inhibitors  (PDEIs),  have  been  used  for treatment  of  ED. It
has been  shown  that oxidative  stress  plays  an  important  role in  the  progression  of  erectile  dysfunction.
Oxidative  stress  can be alleviated  or decreased  by  antioxidant  enzymes.  Therefore,  the present  study
aims  at  investigating  the changes  in  the  activity  of antioxidant  enzymes  such  as  superoxide  dismutase,
catalase,  and  glutathione  reductase  as  well  as  protein  expression  of  glutathione  peroxidase  and  glu-
tathione  S-transferase  after  treatment  of  male  rats  with  a daily  dose  of sildenaﬁl  (1.48 mg/kg),  tadalaﬁl
(0.285  mg/kg)  and  vardenaﬁl  (0.285  mg/kg)  for three  weeks.  In addition,  levels  of  reduced  glutathione  and
malondialdyhyde  (MDA)  were assayed.  The  present  study  showed  that  sildenaﬁl,  vardenaﬁl,  and  tadalaﬁl
treatments  signiﬁcantly  decreased  the  levels  of  glutathione,  MDA  and  the  activity  of glutathione  reduc-
tase.  In addition,  vardenaﬁl  and  sildenaﬁl  increased  the  activity  of  superoxide  dismutase  and  catalase.
Interestingly,  western  immunoblotting  data  showed  that  vardenaﬁl  induced  the activity  of  glutathione
peroxidase  (GPX) and  its protein  expression,  whereas  tadalaﬁl  and  sildenaﬁl  inhibited  such enzyme  activ-
ity and  its  protein  expression.  In addition,  the  protein  expression  of  GST   isozyme  was  markedly  reduced
after treatment  of  rats  with  sildenaﬁl.  It  is concluded  that  ED drugs  induced  the  activities  of  both  SOD  and
catalase which  consequently  decreased  MDA  level.  Therefore,  decrement  in  MDA  levels  could  increase
nitric oxide–cGMP  level  which  in turn  promotes  the erection  mechanism.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Erectile dysfunction (ED) is the inability to maintain penile erec-
ion for satisfactory sexual performance. Phosphodiesterase type-5
PDE-5) is present in most vascular beds as well as cardiac myocytes
43,13,25]. PDE-5 inhibitors have been developed for treatment of
rectile dysfunction through diminishing the degradation of cGMP
8,38,3]. PDE-5 inhibitors are sildenaﬁl citrate (Viagra), tadalaﬁl
Cialis) and vardenaﬁl (Levitra). All over the world, these drugs have
een used extensively in treatment of ED. It has been found that
ardenaﬁl increased intracavernosal pressure more quickly and to
 greater extent than sildenaﬁl in a rabbit model [41,40]. In addi-
ion, vardenaﬁl is more potent and selective biochemically toward
Abbreviations: ED, erectile dysfunction; EDD, erectile dysfunction drugs; PDEIs,
hosphodiesterase inhibitors; PDE-5, phosphodiesterase type-5; MDA, malondi-
ldyhyde; GST, glutathione S-transferase; SOD, superoxide dismutase; CAT, catalase;
OS, reactive oxygen species; GPx, glutathione peroxidase; GSH, glutathione; GR,
lutathione reductase.
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c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ED than sildenaﬁl. Tadalaﬁl is effective for up to 36 h in men  and
has a long-acting inhibition on PDE-5 [16,29].
There is a growing interest among researchers regarding the role
of oxidative stress and reactive oxygen species (ROS) in the patho-
physiological mechanism of ED [48,15]. Oxidative stress occurs
when there is an imbalance between prooxidants and the abil-
ity of the antioxidants to scavenge excess reactive oxygen species
[53,56]. However, its role in ED has not been investigated compre-
hensively. Previous study showed a signiﬁcant association between
the production of reactive oxygen species (ROS) and erectile dys-
function especially in diabetic animal models [27,10]. It has been
found that combined treatment of diabetic ED with PDE5 inhibitors
and antioxidant agents are more effective than PDE5 inhibitors
alone. Treatment of diabetic patients with ED with l-carnitine (an
antioxidant) and sildenaﬁl was  found to reduce monocyte oxida-
tive activity and the amount of endothelial dysfunction markers
[35]. In addition, it has been found that Vitamin E enhanced the
therapeutic effect of the PDE5 inhibitor supporting the potential
use of oxygen free radical scavengers in salvaging erectile function
in diabetic patients [14]. Moreover, combined treatment of diabetic
patients with antioxidants plus sildenaﬁl was found to improve the
action of sildenaﬁl which may  be due to neutralization of reactive
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xygen species [55]. In addition, Incubation of endothelial cells with
ildenaﬁl was found to attenuate the oxidant burden [33]. More-
ver, vardenaﬁl treatment was found to reduce DNA breakage and
xidative stress as well as increased the cGMP levels in the aortic
all [30].
Superoxide dismutase (SOD), an antioxidant enzyme, converts
uperoxide anion (O•−2) to hydrogen peroxide (H2O2) and molec-
lar oxygen (O2) [26]. SOD is a promising therapeutic target for ED
15]. Also, sildenaﬁl was found to reduce superoxide formation and
ncreased levels of cGMP, cAMP and glutathione in corpus caver-
osum of rabbits and in hypertensive rats [49]. In addition, chronic
reatment of rats with sildenaﬁl was found to restore the elevated
iological markers of oxidative stress and cyclooxygenase derived
asoconstrictors to their normal levels [6]. ROS, formed during
egular oxygen molecule metabolism primarily in the vascular
ndothelium, include H2O2 and peroxynitrite (OONO2). Increment
n ROS level was found to inhibit SOD activity which consequently
educes the bioavailable NO concentration through induction of
eroxynitrite level [21].
Recently, it has been found that oxidative stress plays an impor-
ant role in ED which can be alleviated by antioxidant enzymes [32].
herefore, the present study aimed at investigating the alterations
n activities of superoxide dismutase and catalase as antioxidant
nzymes as well as protein expression of glutathione peroxidase
nd glutathione S-transferase after treatment of rats with sildenaﬁl,
ardenaﬁl and/or tadalaﬁl.
. Materials and methods
.1. Chemicals
Sildenaﬁl, tadalaﬁl, vardenaﬁl pills manufactured by Pﬁzer
harmaceutical Company, Lilly Corporation, Schering-Plough Cor-
oration, USA, respectively, were obtained from local drug stores
t Egypt. Sulfosalcylic acid, bis-(3-caboxy-4-nitrophenyl)-disulﬁde,
-chloro-2, 4-dinitrobenzene and all other chemicals were pur-
hased from Sigma Chemical Co., St. Louis, MO,  USA. Monoclonal
ntibodies of glutathione S-transferase  and glutathione peroxi-
ase were obtained from ABCAM, UK.
.2. Animals
Fifty male Sprague–Dawely rats (weighing 100–120 gm)  were
btained from the animal house of Faculty of Medicine, Alexandria
niversity, Alexandria, Egypt. The rats were housed in standard
ages where food and water were provided ad libitum. After a
eriod of acclimation, animals were divided into four groups. The
rst group (11 rats) was used as control (C) and received ddH2O as
ehicle. Thirteen rats in the second, third, and fourth group received
n oral daily dose of sildenaﬁl (1.48 mg/kg), tadalaﬁl (0.285 mg/kg)
nd vardenaﬁl (0.285 mg/kg) respectively, for three weeks. These
oses have been chosen according to the manufacturers of these
rugs. At the end of the experimental period, rats were anesthetized
ith diethyl ether and sacriﬁced by cervical decapitation. The tho-
acic cavity of rats was opened for whole body and liver tissues were
emoved. Also, fasting blood samples were collected in heparinized
ubes and plasma samples were obtained after centrifugation at
000 rpm for 20 min  and stored at −80 ◦C until use.
.3. Enzyme assessments
At the designated time point, the thoracic cavity of rats was
pened for whole body. Liver tissues were vigorously washed in an
ced solution of 0.25 M sucrose, which contained 0.001 M EDTA, to
void contamination from erythrocyte-containing enzymes. Liver
issues were homogenized in 3 vol (w/v) 0.1 M phosphate buffer,eports 2 (2015) 933–938
(pH 7.4) and centrifuged at 12000 × g for 20 min at 4 ◦C. Reduced
glutathione level was  estimated in the supernatant of liver tis-
sue homogenate using sulfosalcylic acid for protein precipitation
and bis-(3-caboxy-4-nitrophenyl)-disulﬁde for color development
[34]. Glutathione reductase activity was  assayed by monitoring the
oxidation of NADPH at 340 nm using the method of James et al.
[24]. A unit of enzyme activity represents 1 nmol of NADPH oxi-
dized/min/mg protein. GST activity was  determined according to
the method of Lee et al. [31]. The conjugate of GSH with l-chloro-2,
4-dinitrobenzene (CDNB) was  measured at 340 nm using a dou-
ble beam spectrophotometer. A unit of enzyme activity is deﬁned
as the amount of enzyme that catalyses the formation of 1 mmol
of CDNB conjugate/mg protein/min under the assay conditions.
Calculations were made using a molar extinction coefﬁcient of
9.6 mM−1 cm−1. The hepatic lipid peroxidation end product, mal-
ondialdehyde (MDA), was measured as thiobarbituric acid reactive
substance (TBARS), according to the method of Tappel and Zalkin
[52]. The color intensity of the reactants (MDA) was measured at
532 nm.  An extinction coefﬁcient of 156,000 M−1 cm−1 was used
for the calculation.
2.4. Glutathione peroxidase
Glutathione peroxidase enzyme activity (GPx; EC. 1.11.1.9) was
assayed according to the method of Chiu et al. [12]. The reaction
mixture (1 mL)  containing 0.05 mL  of the enzyme source, 0.05 M
Tris–HCl buffer (pH 7.6), 1.5 mM GSH, and cumene hydroperoxide
was incubated for 5 min  at 37 ◦C. In another tube, the control sam-
ple was prepared without cumene hydroperoxides and incubated
for 5 min  at 37 ◦C. To both control and test samples, 1.0 mL  of TCA
(15%) were added, while 0.1 mL cumene hydroperoxide was added
to the control only. Both tubes were incubated for 10 min  at 37 ◦C
and centrifuged at 3000 rpm for 20 min. Tris–HCL buffer (pH 8.9)
and 1.5 mM DTNB were added to 1 mL supernatant for both sample
and control. The optical density of the yellow color obtained was
measured at 412 nm within 5 min. Result was expressed as U/gm
tissue.
2.5. Superoxide dismutase activity
SOD activity was  measured according to the method of Sun et al.
[50]. Estimation of SOD activity was  based on the generation of
superoxide radicals produced by xanthine and xanthine oxidase,
which react with nitroblue tetrazolium (NTB) to form formazan
dye. Generated formazan dye was  then measured spectrophoto-
metrically at 560 nm.  The degree of inhibition of this reaction was
expressed as mM/min/ml  plasma.
2.6. Catalase assay
Catalase (CAT) activity was  determined by measuring the
decrease in the absorbance of H2O2 solution decomposed by the
enzyme [4]. The quantity of H2O2 decomposed over speciﬁed time
was calculated using the molar absorbance coefﬁcient. Absorbance
was measured at wavelength 240 nm and catalase activity was
expressed in IU/L plasma.
2.7. Western immunoblotting technique
From pooled sample of each treatment, 20 g of S-9 liver
supernatant proteins were prepared and subjected to 10% SDS-
polyacrylamide gel electrophoresis. Proteins were transblotted to
Hybond-C nitrocellulose membranes (Amersham, UK). The mem-
branes were stained by Ponceau to verify the transfer of comparable
amounts of cellular protein. Nonspeciﬁc binding sites of the mem-
branes were blocked by 5% Bovine Serum Albumin (BSA) for 1 h
S. Sheweita et al. / Toxicology Reports 2 (2015) 933–938 935
Table  1
Changes in the activity of antioxidant enzymes and free radical levels after treatment of rats with a daily dose of tadalaﬁl, vardenaﬁl and/or sildenaﬁl for consecutive three
weeks.
Enzymes Control Tadalaﬁl Vardenaﬁl Sildenaﬁl
GST (Unit /mg  protein) 0.79 ± 0.015 0.79 ± 0.02 0.60 ± 0.017 0.74 ± 0.013
(NS)  (−25%, P < 0.05)** (NS)
Glutathione reductase (nM
oxidized NADPH/mg protein/min)
95.6 ± 2.67 75.0 ± 3.36 46.0 ± 2.1 59.7 ± 1.57
(−22%, P < 0.001)* (−51%, P < 0.001)* (−38%, P < 0.001)*
Glutathione peroxidase
(IU/g tissue)
34.2 ± 2.2 21.9 ± 3.2 42.7 ± 3.0 24.6 ± 3.1
(−36%, P < 0.05)** (+25%, P < 0.05)** (−28%, P < 0.05)**
Glutathione (M GSH/g liver) 2.1 ± 0.13 1.65 ± 0.09 1.03 ± 0.04 1.36 ± 0.02
(−23%, P < 0.001)* (−51%, P < 0.001)* (−36%, P < 0.001)*
TBARS (M/g  liver) 16.1 ± 0.48 11.6 ± 0.29 10.3 ± 0.38 12.36 ± 0.11
(−28%, P < 0.001)* (−36%, P < 0.001)* (−23%, P < 0.001)*
Catalase activity
(IUnit/L)
168.9 ± 0.8 247.0 ± 3.4 269.1 ± 4.73 223.0 ± 0.9
(+47%, P < 0.001)* (+56%, P < 0.001)* (+32%, P < 0.001)*
SOD activity (mM/min/mL) 2.5 ± 0.039 2.7 ± 0.20 3.5 ± 0.12 2.9 ± 0.09
(NS) (+35%, P < 0.001)* (+17%, P < 0.05)**
Values are expressed as Mean ± SEM.
NS: values are not signiﬁcant statistically compared to the control group where P > 0.05.
* Values are signiﬁcantly different compared to control group where P < 0.05.
** Values are signiﬁcantly different compared to control group where P < 0.001.







sB)  Glutathione peroxidase (GPx3 isozyme). In both ﬁgures A and B, Lanes 1–4 repre
ats,  respectively. The band intensity was measured using Quantity one software pr
t 37 ◦C. The blots were then incubated with speciﬁc anti- rabbit
rimary antibodies against GST  isoenzyme and Gpx3, at a dilu-
ion of 1:1000 incubated overnight at room temperature, followed
y a 2-h incubation period with anti- rabbit peroxidase-labelled
econdary antibody at a dilution of 1:15000 at room temperature. the pooled proteins of matched control, tadalaﬁl, vardenaﬁl, and sildenaﬁl-treated
.
Both GST  and glutathione peroxidase isozymes were visualized
after binding with their speciﬁc monoclonal antibodies. Chemilu-
minescence signals were detected according to the manufacturer’s
instructions (Abcam, UK). The band intensity was measured using
quantity one software program.










sig. 2. Histopathological examination showed moderate inﬂammation and marked
o  changes in the liver of tadalaﬁl-treated rats.
.8. Histopathological examination of liver tissues
The liver tissues were ﬁxed with 2.5% glutaraldehyde in 0.1 M
hosphate buffer for 24 h. Blocks of liver tissue were taken from
he median lobe and prepared for embedding in glycol methacry-
ate (Historesin, Leica) using standard techniques. Subsequently,
ections of 5 m thicknesses were obtained and stained with Eosin
nd Hematoxylin dyes for microscopic assessment. The histological
ections were examined under a light microscope using a 121 inter-
ection grid placed at the ocular lens, coupled to a 100× objective.is in the liver tissues of male rats after treatment with vardenaﬁl and sildenaﬁl with
The hepatic parenchyma was classiﬁed as one of the following: hep-
atocyte cytoplasm or degenerative hepatocytes, central vein, portal
space, and inﬂammatory inﬁltrate.
2.9. Statistical analysisMeans and standard errors of each treatment were calculated
and compared by a Student’s t-test. The level of all signiﬁcances for
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. Results
The present study showed that MDA  levels were signiﬁcantly
ecreased by 28, 36 and 23% after treatment of rats with tadalaﬁl,
ardenaﬁl, and sildenaﬁl, respectively (Table 1). On the other
and, vardenaﬁl and sildenaﬁl signiﬁcantly increased the activ-
ty of superoxide dismutase (SOD) by 35, 17% and catalase by
6, 32%, respectively (Table 1). Tadalaﬁl treatment did not change
OD activity and increased catalase by 47%. The activity of GR and
SH levels were markedly decreased after treatment of rats with
adalaﬁl, vardenaﬁl, and sildenaﬁl by 22, 51, 38 and 23, 51, and 36%,
espectively (Table 1). There are different isozymes of GST and their
otal activities did not change after treatment of rats with either
adalaﬁl or sildenaﬁl, whereas vardenaﬁl induced such activity by
5% (Table 1). GST  is one of these isozymes and its protein expres-
ion was potentially decreased after treatment of rats with either
ardenaﬁl or sildenaﬁl treatments, whereas tadalaﬁl did not change
uch expression (Fig. 1A). The activity of glutathione peroxidase
GPX) and its protein expression were inhibited after treatment of
ats with either tadalaﬁl or sildenaﬁl whereas vardenaﬁl induced
uch activity and expression (Table 1 and Fig. 1B). The histopatho-
ogical examination showed that sildenaﬁl citrate and vardenaﬁl
aused inﬂammation and ﬁbrosis in tissues of rat livers (Fig. 2D
nd C), whereas tadalaﬁl did not cause any changes (Fig. 2B).
. Discussion
The role of oxidative stress and reactive oxygen species in the
athophysiological mechanisms of some diseases have been exten-
ively studied [1,23]. Quenching of free radicals by EDD could
ustain the bioavailability of NO for vasodilatation which might
e a new possible mechanism of actions of ED medications since
ost cases of erectile dysfunction (ED) are associated with oxida-
ive stress [57,46,39]. Induction of SOD and CAT activities might
e a defence mechanism to protect the cell against oxidative insult
esulted from high levels of free radicals [37,9,7]. Previous study
howed that sildenaﬁl reduced malondialdyhyde (MDA) levels and
ncreased the activity of antioxidant enzymes in rats [5]. In agree-
ent with this ﬁnding, MDA  levels were signiﬁcantly decreased
fter treatment of rats with tadalaﬁl, vardenaﬁl, and sildenaﬁl.
ecrement in MDA  levels might be due to induction of superox-
de dismutase and catalase activities since tadalaﬁl, vardenaﬁl and
ildenaﬁl signiﬁcantly increased the activities of these enzymes. In
greement with our ﬁnding, sildenaﬁl depresses hydrogen perox-
de generation by inducing the activity of superoxide dismutase
SOD)-mimetic by preventing reactive oxygen species (ROS) gen-
ration [22,18]. Also, it has been found that sildenaﬁl improved
he antioxidants concentrations and reduced oxidative stress in
atients [17]. Moreover, it has been found that tadalaﬁl was  more
ffective than sildenaﬁl because it increased SOD activity in rats
44,36] and decreased MDA  levels in their cavernous tissues [11]. In
ddition, it has been found that tadalaﬁl is not only a PDE5 inhibitor,
ut also act as an effective antioxidant agent for the penis and also
nhibits the production of lipid peroxidation via inhibition of nicoti-
amide adenine dinucleotide phosphate (NADPH) oxidase activity
hich in turn reduces superoxide anion formation [44,28].
Glutathione reductase and glutathione play an important role
n scavenging of free radicals [2,42,47]. The reduced form of glu-
athione (GSH) is the most important cellular antioxidant and is also
n essential cofactor for nitric oxide (NO) synthase that synthesizes
O from l-arginine [19]. Therefore, GSH depletion could lead to
eduction of NO synthesis, and consequently impairs vasodilation
n the corpora cavernosa [51]. In the present study, the activity of GR
nd GSH levels were markedly decreased in liver tissues after treat-
ent of rats with sildenaﬁl, vardenaﬁl and tadalaﬁl. In accordanceeports 2 (2015) 933–938 937
with the present study, it has been found that sildenaﬁl reduced
GSH levels in both prostate and brain tissues of rat [54,20] and in
red blood cell of human [51]. It has been proposed that the total GSH
level is partially dependent on the reduction of the oxidized form
of glutathione (GSSG) to the reduced form (GSH) by glutathione
reductase [45]. It seems that there are different sources of GSH
pool such as GSH synthase and -gluatamyltranspeptidase because
the activity of glutathione reductase is markedly inhibited after the
treatment of rats with ED drugs.
It seems from the present study and others that changes in glu-
tathione peroxidase activity is dependent on animal species since
sildenaﬁl did not change glutathione peroxidase activity in human
erythrocyte [37]. However, glutathione peroxidase (GPX) activity
and its protein expression were inhibited after treatment of rats
with either tadalaﬁl or sildenaﬁl whereas vardenaﬁl induced such
activity and expression of its protein. Therefore, inhibition of glu-
tathione peroxidase, glutathione reductase activities, and depletion
of glutathione levels may  enhance liver toxicity. Supporting this
ﬁnding, the histopathological examination showed that sildenaﬁl
citrate caused inﬂammation and ﬁbrosis in rat liver tissues, whereas
tadalaﬁl did not cause any changes. Therefore, inhibition of GST 
expression after treatment of rats with either sildenaﬁl or varde-
naﬁl might be due to inﬂammation and ﬁbrosis caused by these
drugs. This inhibition might potentiate liver toxicity and probably
other organs since GST  isozyme plays a signiﬁcant role in the pro-
tection of liver against toxicity induced by a wide variety of toxic
compounds [47].
It is concluded that ED drugs decreased free radical levels and
increased the antioxidant capacity by increasing SOD and CAT activ-
ities, which can attenuate the oxidative stress resulted from many
endogenous sources. This attenuation might be a new possible
mechanism that can be added to EDDs beside their action as PDEIs.
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